Simcere Pharmaceutical Group Limited provided unaudited consolidated earnings guidance for the six months ended June 30, 2021. For the six months, it is expected that the Group will record a profit attributable to equity shareholders of the Company of approximately RMB 538 million to RMB 578 million for the six months ended June 30, 2021, representing an increase of approximately RMB 352 million to RMB 392 million, or approximately 190% to 211%, as compared to the profit attributable to equity shareholders of the Company for the same period last year.